Trusted Resources: Education
Scientific literature and patient education texts
RNA-Targeting and Gene Editing Therapies for Transthyretin Amyloidosis
source: Nature Reviews Cardiology
year: 2022
authors: Alberto Aimo, Vincenzo Castiglione, Claudio Rapezzi, Maria Franzini, Giorgia Panichella, Giuseppe Vergaro, Julian Gillmore, Marianna Fontana, Claudio Passino, Michele Emdin
summary/abstract:Transthyretin (TTR) is a tetrameric protein synthesized mostly by the liver and secreted into the plasma. TTR molecules can misfold and form amyloid fibrils in the heart and peripheral nerves, either as a result of gene variants in TTR or as an ageing-related phenomenon, which can lead to amyloid TTR (ATTR) amyloidosis. Some of the proposed strategies to treat ATTR amyloidosis include blocking TTR synthesis in the liver, stabilizing TTR tetramers or disrupting TTR fibrils. Small interfering RNA (siRNA) or antisense oligonucleotide (ASO) technologies have been shown to be highly effective for the blockade of TTR expression in the liver in humans.
The siRNA patisiran and the ASO inotersen have been approved for the treatment of patients with ATTR variant polyneuropathy, regardless of the presence and severity of ATTR cardiomyopathy. Preliminary data show that therapy with patisiran improves the cardiac phenotype rather than only inducing disease stabilization in patients with ATTR variant polyneuropathy and concomitant ATTR cardiomyopathy, and this drug is being evaluated in a phase III clinical trial in patients with ATTR cardiomyopathy. Furthermore, ongoing phase III clinical trials will evaluate another siRNA, vutrisiran, and a novel ASO formulation, eplontersen, in patients with ATTR variant polyneuropathy or ATTR cardiomyopathy. In this Review, we discuss these approaches for TTR silencing in the treatment of ATTR amyloidosis as well as the latest strategy of genome editing with CRISPR-Cas9 to reduce TTR gene expression.
organization: Institute of Life Sciences, Italy; Fondazione Toscana Gabriele Monasterio, Italy; University of Ferrara, Italy; Maria Cecilia Hospital, Italy; University Hospital of Pisa, Italy; National Amyloidosis Centre, University College London, UKDOI: 10.1038/s41569-022-00683-z
read more
Related Content
-
Prof. Philip Hawkins, FMedSciProf. Philip Hawkins is a Professor of M...
-
How Neuropathy Patients Can Cope With a DiagnosisThe presence of peripheral neuropathy sy...
-
Diet and Nutrition in AL AmyloidosisAL amyloidosis patients often have queri...
-
AL Amyloidosis and the Heart by Dr. Tony Urey – ASG Webinar – 5/9https://www.youtube.com/watch?v=vP4wvJq5...
-
Systemic AmyloidosisTissue deposition of protein fibrils cau...
-
Angelo Maiolino, MD, PhDAngelo Maiolino is an Associate Professo...
-
Health Insurance by Monica Fawzy Bryant, Triage Cancer – ASG Webinar – 7/9https://www.youtube.com/watch?v=vP4wvJq5...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.